Uncontrolled proliferation of nearly any cell in a complex animal can be catastrophic, and therefore the expansion of cells is tightly regulated. One mechanism of such regulation is the induction of apoptosis, especially by those cellular events that also promote entry into the cell cycle. Thus, c-Myc (1), E2F (2) , and adenovirus E1A (3) promote apoptosis in fibroblasts, and this has been suggested to be a critical anticancer mechanism (4) . In the immune system, apoptosis of lymphocytes is important not only as a mechanism to offset oncogenesis but also to prevent damage of host tissues by overly aggressive immune mechanisms (5) . Activation of T lymphocytes can therefore promote either cell proliferation or apoptotic cell death (5) . Previous studies using c-Myc antisense oligonucleotides (6) or dominant-negative mutants of c-Myc and Max (7) (which antagonize the functional Myc/Max heterodimer) demonstrated that c-Myc function is required for the process of activationinduced cell death (AICD) 1 in T cells. More recently, we (8) and others (9 -11) showed that activation-induced apoptosis in T cells proceeds via expression of Fas (CD95/Apo-1) and its ligand (FasL) and their subsequent interaction on the cell surface. Similarly, apoptosis triggered by expression of c-Myc in fibroblasts has also recently been shown to depend on signaling via FasL/Fas interaction on the cell surface (12) . Thus, the requirement for c-Myc in AICD indicates a role for c-Myc in the expression of FasL and/or Fas and/or an increased susceptibility to Fas-mediated apoptosis.
Because AICD appears to be regulated primarily at the level of FasL expression (5), we explored the possibility that FasL expression is controlled by c-Myc. Here we report that inhibition of optimal c-Myc expression by treatment of T cells with antisense oligonucleotides corresponding to c-myc effectively blocked activation-induced expression of FasL mRNA and protein. To examine whether the requirement for c-Myc is at the level of transcription, we employed a reporter construct containing 1.2 kb upstream of the human FasL gene (13) and found that this promoter is c-Myc-responsive and -dependent. These data are discussed in terms of the possibility that the FasL gene may be a direct or indirect transcriptional target for c-Myc.
MATERIALS AND METHODS
Reagents and Cells-The T cell hybridoma lines A1.1, parental L1210, and L1210 expressing murine Fas (L1210.Fas) have been described previously (8) . Human leukemic Jurkat cells were obtained from ATCC. Cells were cultured in RPMI 1640, 5% fetal calf serum, 2 mM L-glutamine, 50 mM ␤-mercaptoethanol, 100 units/ml penicillin, 100 g/ml streptomycin (complete medium). Normal murine T cell blasts were generated by dissociating the spleens of C57/B6 mice between frosted glass microscope slides and subsequent hypotonic lysis to remove erythrocytes. After resuspension in complete medium, cells were stimulated for 2 days with 1 g/ml concanavalin A (Sigma), washed once to remove the lectin, and cultured with 100 units/ml recombinant IL-2 (Proleukin, Chiron) for another 5 days to generate T cell blasts. Before being used in an experiment, T cell blasts were purified by Ficoll density centrifugation to remove dead cells.
Phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma, and ionomycin was purchased from Calbiochem. Hamster anti-mouse CD3⑀ (145-2C11) was purified from culture supernatant by protein A affinity chromatography (14) . Normal mouse IgG and biotinylated goat anti-mouse IgG were obtained from Jackson Laboratories (West Grove, PA). Anti-human Fas (CH-11) was obtained from Kamiya (Thousand Oaks, CA). Anti-mouse FasL Kay 10 was a generous gift of Nosheen Alaverdi (Pharmingen, San Diego, CA). The sequence for c-myc antisense (AS) oligonucleotides was 5Ј-CACGTTGAGGGGCAT-3Ј, and the sequence for c-myc nonsense (NS) oligonucleotides was 5Ј-AGTGGCG-GAGACTCT-3Ј. All oligonucleotides were phosphorothionate-derivatized (Quality Controlled Biochemicals, Hopkinton, MA) (6 Cloning of Human FasL Promoter-We have previously described the cloning of the 1.2-kb FasL promoter (13) . Briefly, a 1.2-kb fragment was amplified from pBhFL5H3-1 (15) as template using standard polymerase chain reaction conditions. Polymerase chain reactions were done in a Delta II thermocycler from Ericomp (San Diego, CA). Purified DNA was digested with HindIII and SalI and cloned into the luciferase reporter construct HsLuc (16) .
Luciferase Assays-Transient transfections of Jurkat cells by electroporation and luciferase assay were done as described previously (13) . Briefly, the human FasL HsLuc promoter construct was co-transfected with either (a) pBabe MaxRx, pDOR MycRx, or the combination of both (17) or (b) pSP271 Myc (18) . The DNA was normalized with pBabe empty vector to a total amount of 40 g. For induction of FasL promoter activity, cells were harvested 24 h post-transfection, resuspended in fresh medium, and stimulated with or without PMA (50 ng/ml) and ionomycin (500 ng/ml) for 8 -12 h. Cells were then harvested, washed twice in phosphate-buffered saline, and lysed, and the supernatants were used for detection of luciferase activity with a Monolight 2010 luminometer at the manufacturer's recommended conditions (Analytical Luminescence Laboratory). All experiments were done in triplicate. Transfection efficiencies were normalized by co-transfecting with ␤-galactosidase expression vector (pSV-␤-Gal, Promega).
Jurkat-Tag cells were suspended at 20 ϫ 10 6 /ml in serum-free media, and 500 cells were transferred to a 4-mm electroporation cuvette. Reporter construct plasmid DNA was added (15 g of hFLP-Luc B5 or 10 g of NFAT-Luc) along with either empty vector (20 g of pcDNA3) or c-myc expression vector (20 g of pSP271 Myc). After electroporation, which was performed using 960 microfarads and 240 V, cells were cultured for 24 h in complete media and then stimulated with PMA and ionomycin for 16 h. Cells were harvested, washed, and lysed, and luciferase assays were performed as described above and normalized according to protein content.
Assessment of c-Myc Protein-2 ϫ 10 6 A1.1 cells/group were incubated with 10 M c-myc AS or NS for 12 h. After that, cells were harvested, washed once in phosphate-buffered saline, and then lysed in 100 l of 1ϫ SDS-polyacrylamide gel electrophoresis sample buffer (50 mM Tris, pH 6.8, 100 mM dithiothreitol, 2% SDS, 10% glycerol). Equal volumes of samples (25 l) were separated on a 12% gel and transferred to a nylon membrane (polyvinylidene difluoride, Fisher Scientific, Pittsburgh, PA). Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline, 0.05% sodium azide for 1 h and then incubated with rabbit anti-mouse c-Myc antiserum (1:500) (6) for 4 h at room temperature. Membranes were then washed three times in Tris-buffered saline, 0.05% Tween 20 for 15 min and incubated with a donkey anti-rabbit-horse radish peroxidase conjugate (1:2000, Amersham Pharmacia Biotech) for 1 h. After three washes membranes were incubated with ECL detection solutions (Amersham Pharmacia Biotech) and exposed to x-ray film. To ensure equal loading, membranes were then stripped and reprobed for actin (mouse anti-actin, 1:2000, Amersham Pharmacia Biotech).
Analysis of FasL Expression and Function-Murine T cell hybridomas (1 ϫ 10 7 cells/group) were preincubated with 20 M c-myc AS or NS for 4 h and then stimulated with anti-CD3 for 4 h. Total RNA was isolated and analyzed for FasL mRNA by reverse transcriptase-polymerase chain reaction as described previously (19, 20) .
To detect FasL by antibody staining, A1.1 cells were preincubated with 20 M c-myc AS or NS or medium control for 4 h prior to stimulation with anti-CD3 for 5 h. After that, cells were harvested; washed in phosphate-buffered saline, 1% calf serum, 0.05% sodium azide (wash buffer); and incubated for 15 min at room temperature with 50 g/ml normal hamster immunoglobulin in wash buffer to block nonspecific binding. Cells were then placed on ice, and anti-FasL mAb Kay 10 or normal mouse IgG was added (5 g/ml final concentration). After 30 min cells were washed, and antibody binding was detected with goat anti-mouse biotin (2.5 g/ml) and streptavidin-fluorescein conjugate (5 g/ml), followed by FACS analysis.
To evaluate AICD, cells were pretreated with either 20 M c-myc AS or NS for 4 h prior to stimulation with anti-CD3 for 18 h. Cells were then harvested, and cell death was assessed by propidium iodide uptake (21) . No effect of AS or NS c-myc oligonucleotides was observed in anti-Fas-induced apoptosis in Jurkat cells (data not shown).
Activation-induced FasL expression on murine T cells was assessed by determining the ability of these cells to cause DNA fragmentation in Fas ϩ target cells as described previously (8) . 
RESULTS

Inhibition of c-Myc Expression Blocks Activation-induced FasL but Not Fas Expression in A1.1 T Cells-Our
previous studies showed that treatment of the A1.1 T cell hybridoma with antisense oligodeoxynucleotides corresponding to c-myc effectively blocks apoptosis induced by ligation of the T cell receptor on these cells (6) , which proceeds via a Fas/FasL interaction (8) . We therefore examined the effects of antisense and control oligonucleotides on Fas and FasL expression in these cells. As shown in Fig. 1 , treatment with antisense oligodeoxynucleotides corresponding to c-myc (AS c-myc) inhibited c-Myc protein expression (Fig. 1B) and activation-induced apoptosis in these cells (Fig. 1A) . Control oligonucleotides with the same base composition but a different sequence (NS c-myc) had no effect in either case. As shown in Fig. 2 , treatment of the A1.1 cells with AS c-myc also blocked the induction of FasL mRNA expression ( Fig. 2A) and functional FasL expression, as assessed by killing of Fas ϩ target cells (Fig. 2B) . AS c-myc similarly blocked FasL protein expression on activated A1.1 cells as determined by staining with an anti-FasL antibody and FACS analysis (Fig. 2C) . Control oligonucleotides (NS c-myc) had no effect on any of the above features. In contrast to FasL expression, treatment of A1.1 cells with AS c-myc had no effect on activation-induced Fas mRNA expression (Fig. 2A) . These data support the idea that c-Myc is required for activationinduced FasL but not Fas expression.
To further examine the apparent requirement for c-Myc in activation-induced FasL expression in T cells, we employed normal murine T cells that had been previously activated for 7 days (see "Materials and Methods"). Restimulation of these (Fig. 3A) . As we had previously shown in A1.1 cells (6), treatment of the T cells with AS c-myc, but not with NS c-myc, effectively blocked activationinduced apoptosis (Fig. 3A) . Further, treatment of activated T cells with AS c-myc prevented activation-induced FasL expression (Fig. 3B) . NS c-myc had no effect in either assay.
The FasL Promoter Requires and Is Responsive to c-Myc Expression-To determine whether the requirement for c-Myc for activation-induced expression of FasL is at the level of FasL transcription, we employed a FasL promoter reporter comprising 1.2 kb upstream of the human FasL gene (13) . When transfected into the Jurkat human leukemic T cell line, the FasL reporter showed a consistent increase in luciferase activity after stimulation with PMA/ionomycin (Fig. 4A) . This finding is in agreement with the previously described observation that activation of Jurkat cells leads to expression of FasL (9) .
If c-Myc transcriptionally regulates FasL, then overexpression of c-Myc should lead to increased FasL reporter activity. Jurkat cells were therefore co-transfected with the 1.2-kb FasL promoter reporter construct and a c-Myc expression vector. Overexpression of c-Myc enhanced both basal and PMA/ionomycin-induced FasL promoter activity in a gene dosage-dependent manner (Fig. 4B) . Thus, high levels of c-Myc expression are capable of inducing FasL promoter activity, indicating that c-Myc may play a role in the regulation of FasL gene transcription.
To test the specificity of the effect of c-Myc for the FasL promoter, we compared effects on three promoter reporter constructs (Fig. 4C) . Whereas c-Myc co-expression induced significant induction of the FasL promoter, it had no significant effect on expression of either an IL-2 promoter (not shown) or an NFAT-responsive reporter. Further, this lack of an effect of c-Myc co-expression was also seen upon stimulation of the NFAT reporter by treatment with PMA plus ionomycin. Thus, c-Myc participates in the activation of the FasL promoter but not other irrelevant promoters in this assay.
c-Myc and Max have been found to heterodimerize through their leucine zipper regions at their C-terminal ends, and this complex is responsible for the transcriptional activity (22, 23) . The exchange mutant, MaxRx, in which the leucine zipper region of Max has been exchanged with that of c-Myc, does not bind to c-Myc and can only interact with wild type Max (24) (Fig. 5A) . Similarly, its reciprocal mutant MycRx interacts with Myc but does not heterodimerize with Max (24) . These hybrids can thereby act as dominant-negative inhibitors of Myc/Max function in different cellular systems (7, 17, 24) . We have previously shown that inhibition of Myc/Max function by these dominant-negative mutants prevents activation-induced cell death in T cell hybridomas (7) . To assess whether a functional Myc/Max interaction is required for activation-driven induction of the FasL promoter, we co-transfected MaxRx, its reciprocal partner MycRx, or a combination of both into Jurkat cells and analyzed activation-induced promoter activity. Transient transfection of MaxRx consistently led to inhibition of activation-induced luciferase activity (Fig. 5B) , indicating a requirement for Myc/Max in FasL promoter activation. Similarly, transient expression of MycRx significantly inhibited activation-induced FasL promoter activity, although to a lesser extent than did MaxRx (Fig. 5B ). This observation is in agreement with previously reported findings that MycRx is a less potent inhibitor of Myc/Max function than is MaxRx (24) . Activation of the FasL promoter followed the predicted pattern (Fig. 5A) as the inhibitory effect of MaxRx or MycRx expression on the FasL promoter activity was abolished upon coexpression of both (Fig. 5B) . In contrast, neither of these reciprocal exchange mutants had any effect on expression of an NFATreporter construct (data not shown).
Recently, a Max-interacting protein, Mnt (Fig. 5A) , was identified as a repressor of Myc function (25) . To determine whether Mnt/Max interactions regulate the FasL promoter, we co-transfected Mnt with the 1.2-kb FasL reporter construct. We observed that expression of Mnt inhibited activation-induced FasL reporter activity (Fig. 5C) .
The FasL Promoter Lacks Consensus c-Myc Binding Sequences-Myc/Max heterodimers regulate gene transcription via interaction with a defined promoter motif. The canonical sequence CACGTG and its variations as determined by Myc/ DNA binding studies (26) are uniformly absent from the FasL promoter sequence (data not shown). Thus, it is possible that Myc acts indirectly to regulate FasL gene expression via regulation of another factor. Alternatively, Myc/Max may bind to a different sequence in the promoter to regulate FasL transcription. In either case the biological outcome is the same: activation-induced expression of FasL in T cells is dependent on c-Myc.
To partially discriminate between these possibilities, we examined activation-induced FasL mRNA expression in cells treated with cycloheximide to prevent effects of other transcription factors induced following activation. In the experiment shown in Fig. 6 , AS c-myc oligonucleotide pretreatment prevented expression of FasL, whereas NS c-myc did not. Cycloheximide did not interfere with this activation-induced, c-Mycdependent expression of FasL. Thus, transcription and translation of proteins induced by activation (including c-Mycdependent protein expression) are not required for FasL mRNA expression following activation. This provides support for the idea that Myc/Max acts directly on the FasL promoter to induce FasL expression.
DISCUSSION
When T lymphocytes are optimally activated via ligation of the T cell receptor, they produce cytokines and proliferate, a phenomenon that is central to the induction of an antigenspecific immune response. However, since the original studies of Russell et al. (27) and Lenardo (28) , it has been recognized that restimulation of a previously activated T cell can result in AICD. Presumably, this phenomenon contributes to immune regulation and the control of activated lymphocyte numbers. Intuitively, it may be reasoned that because only activated T cells pose a potential threat to immune homeostasis, it is only those cells that are in a state of activation (e.g. expressing c-Myc) that are susceptible to AICD.
How does prior activation contribute to the sensitization of T cells to AICD? Recently, it was shown that previously activated T cells exposed to IL-2 down-regulate c-Flip, an endogenous inhibitor of Fas-mediated apoptosis (29) . Thus, an increase in sensitivity to Fas is one aspect of this effect. Here we have shown another: expression of c-Myc in activated T cells contributes to the transcriptional activation of the FasL promoter. This accounts for the requirement for c-Myc in AICD and provides a mechanism for the relationship between FasL expression and the prior activation status of the T cell.
The observation that c-Myc is required for activation-induced FasL expression and AICD in T cells helps to account for the ability of transforming growth factor ␤ to block this process (30) , a phenomenon that may have a role in producing resistance of Th2 T cells to AICD and allowing their proliferation (31) . Recently, we showed that transforming growth factor ␤ inhibits c-Myc expression in T hybridoma cells and that enforced expression of c-Myc restores AICD and FasL expression (30) .
In T cell hybridomas and previously activated T cells, c-Myc expression is constitutive 2 , and such cells are susceptible to activation-induced apoptosis (8 -11) , presumably at least in part for this reason. This suggests that activation-induced FasL gene expression requires other transcription factors in addition to Myc/Max. Candidates include calcineurin-activated transcription factors such as NFAT as our previous findings (21) and those of others (9, 32) showed that activation-induced FasL expression is cyclosporin A-and FK506-sensitive. Recently, Latinis et al. (33) reported that the region 486 base pairs upstream of the transcription start site in the FasL promoter contains two NFAT sites and that mutating these sites abrogated FasL reporter activity. In addition, we have recently shown that activation of NF-B is important for optimal activation-induced FasL expression, due to an NF-B site in the 1.2-kb promoter (34) .
Several genes have been shown to be regulated by the "classical" Myc E-box containing enhancer elements including prothymosin ␣, ornithine decarboxylase, elongation initiation factors 2a and 4E, p53, cyclin D1, and Cdc25 (35) (36) (37) (38) (39) (40) (41) (42) . The ornithine decarboxylase gene is directly induced by the Myc/ Max heterodimer through two c-Myc recognition sites in its first intron. Overexpression of ornithine decarboxylase in cell lines is transforming (43) and also appears to mediate c-Mycmediated susceptibility to apoptosis induced by IL-3 withdrawal (44) . Another recently identified target gene of the c-Myc/Max heterodimer is cdc25A, a cyclin-dependent, kinaseactivating phosphatase that plays a crucial role in cell cycle progression. c-Myc/Max heterodimers bind directly to the cdc25A promoter through Myc/Max consensus sequences and activate transcription (45) . Cdc25A can also mediate transformation and appears to promote c-Myc-induced apoptosis in fibroblasts. In general, these studies point to a role for cell cycle progression in some forms of c-Myc-induced apoptosis, and some investigators have therefore suggested that such apoptosis is caused by inappropriate entry into the cell cycle through a cell cycle checkpoint (46) . Our finding that c-Myc regulates the expression of FasL in T cells connects c-Myc to apoptotic cell death through engagement of the Fas-mediated apoptotic pathway. Whether any of these genes or another gene is responsible for indirectly activating the FasL promoter is not known. Alternatively, c-Myc may act directly on the promoter via a noncanonical site.
In addition to activation-induced cell death in T cells, fibroblasts are probably the most extensively studied system for Myc-induced apoptosis (1) . The recent finding that Myc-induced apoptosis in serum-starved fibroblasts is dependent on Fas/FasL interactions (12) helps to support our finding that fasL is a target gene of c-Myc. These authors, however, were reportedly unable to measure the very low levels of FasL expression in these cells and did not observe changes upon c-Myc expression.
Cell types other than T cells are capable of expressing FasL. Of particular interest is the finding that tumor cells such as colon carcinomas (47) , melanomas (48) , and lung carcinomas (49) can express FasL in a constitutive manner. Although we expect that these transformed cells constitutively express cMyc, they presumably lack other T cell receptor-derived signals. It is possible that c-Myc expression in these cell types is sufficient for FasL expression or that activation-induced signals are replaced by others. Detailed analysis of FasL expression in these cell types should bring further insight into the alternative regulation of FasL expression in non-T cells. Many tumor cells are insensitive to Fas cross-linking and/or express low levels of Fas (47, 48) . Nevertheless, FasL expression on tumor cells can have immunological consequences resulting either in inhibition of antitumor immunity (47) (48) (49) or FasLinduced granulocytosis (50) . Thus, the inhibition of c-Myc expression in such cells might effectively down-regulate FasL expression, providing an attractive route to the generation of effective antitumor responses.
